University of Vermont

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1791-01-01

Employees: 51

Market Cap: -

Website: http://www.uvm.edu

Clinical Trials

Effectiveness of Aprepitant in Addition to Ondansetron in the Prevention of Nausea and Vomiting Caused by Upper Abdominal Radiotherapy

Phase 2

Completed

Conditions: Nausea
Vomiting

Interventions: Drug: aprepitant
Drug: Ondansetron

First Posted Date: 2009-09-03

Last Posted Date: 2017-12-05

Lead Sponsor: University of Vermont

Target Recruit Count: 52

Registration Number: NCT00970905

Locations: 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States

Statins and Breast Cancer Biomarkers

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Placebo
Drug: Atorvastatin

First Posted Date: 2009-06-04

Last Posted Date: 2010-02-11

Lead Sponsor: University of Vermont

Target Recruit Count: 100

Registration Number: NCT00914017

Locations: 🇺🇸
Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸
Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States

and more 4 locations

Computer-Assisted Stop-Smoking Program in Helping Doctors Counsel Patients Who Smoke Cigarettes

Phase 2

Conditions: Tobacco Use Disorder

First Posted Date: 2009-03-19

Last Posted Date: 2013-09-20

Lead Sponsor: University of Vermont

Target Recruit Count: 630

Registration Number: NCT00865553

Locations: 🇺🇸
Vermont Cancer Center at University of Vermont, Burlington, Vermont, United States

Carbon Monoxide Monitoring and Emergency Treatment

Not Applicable

Conditions: Carbon Monoxide Poisoning

Interventions: Device: Continuous Positive Airway Pressure
Device: Non-rebreather oxygen mask

First Posted Date: 2009-02-11

Last Posted Date: 2010-04-02

Lead Sponsor: University of Vermont

Target Recruit Count: 40

Registration Number: NCT00841165

Locations: 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States

Using Functional MRI to Evaluate Cognitive Behavioral Therapy Treatment Response in Adults With Chronic Pain

Phase 1

Completed

Conditions: Chronic Pain

Interventions: Behavioral: Group cognitive behavioral therapy
Behavioral: Pain education

First Posted Date: 2008-11-24

Last Posted Date: 2013-02-18

Lead Sponsor: University of Vermont

Target Recruit Count: 40

Registration Number: NCT00796536

Locations: 🇺🇸
MindBody Medicine Clinic, Burlington, Vermont, United States

Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)

Phase 2

Terminated

Conditions: Asthma
Obesity

Interventions: Drug: Placebo
Drug: Pioglitazone

First Posted Date: 2008-11-07

Last Posted Date: 2015-02-26

Lead Sponsor: University of Vermont

Target Recruit Count: 28

Registration Number: NCT00787644

Locations: 🇺🇸
The Vermont Lung Center at the University of Vermont, Colchester, Vermont, United States

Bone Turnover in Type 2 Diabetes Patients

Phase 4

Conditions: Type 2 Diabetes

Interventions: Drug: Placebo
Drug: Sitagliptin

First Posted Date: 2008-08-11

Last Posted Date: 2010-06-28

Lead Sponsor: University of Vermont

Target Recruit Count: 20

Registration Number: NCT00732121

Locations: 🇺🇸
University of Vermont, South Burlington, Vermont, United States

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

Early Phase 1

Completed

Conditions: Breast Cancer
Angiogenesis

Interventions: Drug: Aspirin

First Posted Date: 2008-08-04

Last Posted Date: 2020-09-17

Lead Sponsor: University of Vermont

Target Recruit Count: 11

Registration Number: NCT00727948

Locations: 🇺🇸
University of Vermont, Burlington, Vermont, United States

Role of Leukotrienes and Adenosine in Hyperpnea-induced Bronchospasm

Completed

Conditions: Asthma, Exercise Induced

Interventions: Procedure: Hyperpnea challenge

First Posted Date: 2008-07-04

Last Posted Date: 2016-10-31

Lead Sponsor: University of Vermont

Target Recruit Count: 8

Registration Number: NCT00710255

Locations: 🇺🇸
Vermont Lung Center, Colchester, Vermont, United States

Pioglitazone Incretin Study

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Pioglitazone
Drug: Placebo

First Posted Date: 2008-04-11

Last Posted Date: 2011-02-02

Lead Sponsor: University of Vermont

Target Recruit Count: 24

Registration Number: NCT00656864

Locations: 🇺🇸
University of Vermont, South Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy